Why Low-Dose Rivaroxaban Failed in Advanced CKD Patients

Many patients with advanced chronic kidney disease (CKD) face a high risk of fatal cardiovascular events. Consequently, researchers constantly seek effective therapies to protect this vulnerable patient population. Specifically, clinicians wanted to know if low-dose rivaroxaban could lower these cardiovascular risks. However, a new clinical trial provides disappointing news for kidney specialists worldwide.

The Design of the TRACK Trial

The Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) trial examined this issue. Specifically, investigators recruited 1,458 adult patients from 90 centers across 12 countries. These participants had advanced CKD stage 4 or 5 or required regular dialysis. In addition, all patients had established cardiovascular risk factors like diabetes or coronary artery disease. Therefore, this cohort represented patients with exceptionally high cardiovascular risk. The researchers randomized these patients into two equal groups. First, one group received 2.5 mg of rivaroxaban twice daily. Second, the other group received a matching placebo.

Why the Trial Stopped Early

However, the steering committee stopped the trial early on August 7, 2025. They made this decision because interim analyses showed a clear lack of efficacy. Indeed, the primary outcome did not differ significantly between the two groups. Specifically, the primary composite outcome occurred in 22.6% of the rivaroxaban group. Meanwhile, 20.7% of the placebo group experienced the same composite events. This resulted in a non-significant hazard ratio of 1.09. Consequently, the treatment failed to offer any cardiovascular protection.

Major Bleeding Risks with Low-Dose Rivaroxaban

Although the drug provided no benefit, it significantly increased safety concerns. Specifically, major bleeding events occurred in 8.8% of the rivaroxaban group. In contrast, only 6.0% of the placebo group suffered major bleeding. Therefore, patients taking the active drug faced a much higher bleeding risk. This safety concern resulted in a hazard ratio of 1.51. Ultimately, the trial highlights the delicate balance of antithrombotic therapy in advanced renal disease. Thus, nephrologists must exercise extreme caution when considering anticoagulation for these patients.

Clinical Implications for Indian Practitioners

Advanced kidney disease represents a massive clinical burden in India. Consequently, Indian physicians frequently manage patients with concurrent kidney and heart issues. These physicians often prescribe antithrombotic agents to prevent strokes or heart attacks. However, the TRACK trial highlights that standard assumptions do not apply to advanced CKD. Because renal impairment alters drug clearance, it dramatically increases bleeding risks. Therefore, Indian practitioners should avoid prescribing this medication for primary cardioprotection in this subgroup. Instead, clinicians must focus on optimizing traditional risk factors like blood pressure and diabetes.

Frequently Asked Questions

Q1: Why did the investigators stop the TRACK trial early?

The steering committee stopped the trial early because interim analyses revealed a clear lack of efficacy. Specifically, low-dose rivaroxaban did not reduce the primary composite cardiovascular outcome compared to the placebo group.

Q2: What was the primary safety concern associated with low-dose rivaroxaban in the trial?

The primary safety concern was a significantly higher rate of major bleeding. Specifically, major bleeding occurred in 8.8% of the treatment group compared to only 6.0% in the placebo group.

Q3: How do the results of the TRACK trial affect clinical practice for patients with advanced CKD?

Therefore, clinicians should avoid prescribing low-dose rivaroxaban for primary cardiovascular protection in patients with advanced chronic kidney disease. This is because the drug offers no clinical benefit while significantly increasing the risk of severe bleeding.

References

1. Badve SV et al. Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. JAMA. 2026 Jun 04. doi: 10.1001/jama.2026.9379. PMID: 42240165.
2. Bansal N, Winkelmayer WC. Rivaroxaban for cardiovascular disease prevention in chronic kidney disease: high risk, but no reward? JAMA. 2026 Jun 04. doi: 10.1001/jama.2026.9380.
3. ClinicalTrials.gov. Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK). Identifier: NCT03969953.